Chief Medical Officer · Avalo Therapeutics, Inc. (AVTX)

Mittie FACR

A named executive officer of Avalo Therapeutics in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$1,780,557

Salary $512,500Stock awards $0

FY2024: $3,033,757

3rd of 4 named executive officers at Avalo Therapeutics by FY2025 total.

4 named officers on file for Avalo Therapeutics, FY2025

Mittie FACR’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Avalo Therapeutics’s whole pay program stands against its peers

  • Avalo Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AVTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 10, 2026 (DEF 14A).

Free

Get Mittie FACR’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Mittie FACR compensation by year

Avalo Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Avalo Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$231,061$512,500
Bonus$0$0
Stock awards$0$0
Option awards$2,586,696$1,030,429
Non-equity incentive$216,000$229,600
Pension and deferred compensation$0$0
All other$0$8,028
Total$3,033,757$1,780,557

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Avalo Therapeutics, Inc. DEF 14A filed April 10, 2026, accession 0001534120-26-000022, and prior-year filings.

How this page was built: the Avalo Therapeutics, Inc. filed document, accession 0001534120-26-000022. Every figure is read from that document and cited to the page and table it appears in. Filed April 10, 2026.

$3.0M
$1.8M
FY24
FY25
SalaryNon-equity incentiveOption awardsAll other

Avalo Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Garry NeilChief Executive Officer, President and principal executive officer$3,807,581
Taylor BoydChief Business Officer$3,219,751
Mittie FACR · this pageChief Medical Officer$1,780,557
Mittie DoyleChief Medical Officer$1,780,557

The full Avalo Therapeutics compensation record

free company brief

This page is one person within Avalo Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Avalo Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mittie FACR's compensation dossier · One-time report. No refunds.